AR043772A1 - Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso - Google Patents

Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso

Info

Publication number
AR043772A1
AR043772A1 ARP040100981A ARP040100981A AR043772A1 AR 043772 A1 AR043772 A1 AR 043772A1 AR P040100981 A ARP040100981 A AR P040100981A AR P040100981 A ARP040100981 A AR P040100981A AR 043772 A1 AR043772 A1 AR 043772A1
Authority
AR
Argentina
Prior art keywords
ifa
agent
drugs
cocoa powder
formulation according
Prior art date
Application number
ARP040100981A
Other languages
English (en)
Spanish (es)
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of AR043772A1 publication Critical patent/AR043772A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
ARP040100981A 2003-03-26 2004-03-24 Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso AR043772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof

Publications (1)

Publication Number Publication Date
AR043772A1 true AR043772A1 (es) 2005-08-10

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100981A AR043772A1 (es) 2003-03-26 2004-03-24 Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso

Country Status (13)

Country Link
EP (1) EP1605921A1 (xx)
JP (2) JP2006521348A (xx)
CN (1) CN1764440A (xx)
AR (1) AR043772A1 (xx)
AU (1) AU2004224557B2 (xx)
BR (1) BRPI0408655A (xx)
CA (1) CA2519155A1 (xx)
CL (1) CL2004000564A1 (xx)
MX (1) MXPA05010196A (xx)
SE (1) SE0300831D0 (xx)
TW (1) TW200503782A (xx)
WO (1) WO2004084865A1 (xx)
ZA (1) ZA200507719B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP5558712B2 (ja) * 2005-08-02 2014-07-23 ドロサファーム アクチェンゲゼルシャフト インドメタシン及び／又はアセメタシンを含む医薬組成物
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CN102919739B (zh) 2007-06-13 2014-07-02 大塚制药株式会社 含雌马酚的提取物、其制备方法、雌马酚的提取方法及含雌马酚的食品
CN101444273B (zh) * 2007-11-22 2013-04-24 何煜 一种保健品口腔速释制剂及其制造方法
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
WO2010144943A1 (en) * 2009-05-20 2010-12-23 Ozpharma Pty Ltd Buccal and/or sublingual therapeutic formulation
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
WO2014135967A1 (en) 2013-03-06 2014-09-12 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (zh) * 2013-11-01 2015-11-25 阳波 咖啡味甲硝唑口香糖
EP3154529B1 (en) * 2014-06-10 2020-07-08 Capsugel Belgium NV Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
EP3226845A1 (en) 2014-12-04 2017-10-11 Capsugel Belgium NV Lipid multiparticulate formulations
JP6334482B2 (ja) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 固形剤とその製造方法
AU2016367036B2 (en) * 2015-12-09 2019-04-18 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
JP6917310B2 (ja) * 2015-12-09 2021-08-11 ポビバ コーポレーションPoviva Corp. 脂溶性の活性物質を含む安定なレディ・トゥ・ドリンク飲料組成物
AU2017361129B2 (en) * 2016-11-18 2023-11-09 Telethon Kids Institute Taste masking product
CA3092458C (en) * 2018-03-01 2024-01-30 Lts Lohmann Therapie-Systeme Ag Oral dosage form containing theobromine-free cocoa
CN109053718B (zh) * 2018-08-09 2022-06-03 天津理工大学 一种罗格列酮糖精盐及其制备方法
CN111729087A (zh) * 2020-07-24 2020-10-02 成都大学 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (ja) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk 口内薬
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
SE0300831D0 (sv) 2003-03-26
TW200503782A (en) 2005-02-01
CA2519155A1 (en) 2004-10-07
ZA200507719B (en) 2007-09-26
CN1764440A (zh) 2006-04-26
BRPI0408655A (pt) 2006-03-28
WO2004084865A1 (en) 2004-10-07
JP2006521348A (ja) 2006-09-21
AU2004224557A1 (en) 2004-10-07
MXPA05010196A (es) 2005-11-08
CL2004000564A1 (es) 2005-02-04
JP2011079841A (ja) 2011-04-21
EP1605921A1 (en) 2005-12-21
AU2004224557B2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
AR043772A1 (es) Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso
KR101595139B1 (ko) 치은 웨이퍼
US6626669B2 (en) Oral therapeutic delivery appliance
ES2232886T3 (es) Formulaciones de dosificacion de cesion controlada en un momento especifico y metodo para preparar las mismas.
ES2355439T3 (es) Parche bioerosionable.
ES2328115T3 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana.
WO2005046640A3 (en) Multi-site drug delivery platform
Rathbone et al. Overview of oral mucosal delivery
JP2009518374A (ja) 活性薬剤、特にジクロフェナクの経皮投与
HUP0203733A2 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
JP2008505977A (ja) 治療薬及び／又は健康増進薬の膣送達用被覆経膣デバイス
EP1455759A2 (en) Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
DE60133319D1 (de) Mehrfach beschichete pharmazeutische dosierungsform
JP2011125719A (ja) 移植片用の治療薬カプセル
CN108066305A (zh) 改善口崩片硬度和崩解的方法和定位释放口腔崩解片
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
EP3068450B1 (de) Zahnprothese als darreichungsform zur behandlung chronischer erkrankungen
Thulluru et al. Sublingual tablets-an updated review
RU2668690C2 (ru) Дентальная накладка
US20100172956A1 (en) Dissolving strip for oral mucosa as a systemic drug delivery route
JP2006232770A (ja) 外用組成物及びそれを含有する外用剤
EP1257232A2 (en) Oral therapeutic delivery appliance
Shaikh et al. A REVIEW ON BUCOADHESIVE DRUG DELIVERY SYSTEM
ZO et al. An Overview on Buccal Drug Delivery System
Chotaliya OVERVIEW OF SUBLINGUAL TABLETS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal